China Healthcare: Globalization of Innovative Drugs and Recovery in Outsourcing Demand Are the Main Themes

Overview

This report is Morgan Stanley's Asia Summer School 2026 investor material on China's healthcare sector, covering pharmaceuticals, biotechnology, cro/cdmo, medical devices, internet healthcare, healthcare services, traditional Chinese medicine, retail pharmacies, distribution, and active pharmaceutical ingredients. The central theme is that China's healthcare sector continues to offer structural investment opportunities amid the interplay of innovative-drug globalization, outsourced clinical research and development, domestic substitution and overseas expansion of medical devices, policy reform, and industry consolidation.

Core views

The core views include: First, global recognition of China's innovative drugs is moving from engineering capabilities into the Innovation 2.0 phase, with transaction models expanding from out-licensing to NewCos, co-development, co-commercialization, and strategic alliances. Second, the patent-expiry gap at global pharmaceutical companies creates demand, while the financial resilience, talent supply, publication quality, and clinical cost advantages of Chinese biotechnology companies provide supply-side support. Third, cro/cdmo benefits from higher global R&D outsourcing rates, growth in clinical trial initiations in China, cost efficiency, and regulatory advantages. Fourth, medical devices benefit from a domestic market of approximately RMB1.2 trillion, improving hospital capital expenditure, and rising overseas revenue contributions. Fifth, traditional Chinese medicine, retail pharmacies, distribution, and active pharmaceutical ingredients remain under pressure, but cash flow, dividends, industry consolidation, improved compliance, and export exposure create differentiated opportunities.

Analysis framework

The report combines a top-down industry framework with bottom-up company case studies: it first compares the size and growth drivers of the Chinese and global pharmaceutical, medical device, and cro/cdmo markets; then uses cases including Hengrui, CSPC, 3SBio, and Hansoh to illustrate transaction structures for the globalization of innovative drugs; and subsequently tracks policy events, academic conferences, medical insurance negotiations, DRG/DIP, VBP, hospital capital expenditure surveys, and pharmacy operating data to form views on sub-industry opportunities and risks.

Methodology notes

• Industry CycleTAM and Growth Driver Analysis

  Assess long-term market potential using the size and growth rates of the Chinese and global pharmaceutical, medical device, and cro/cdmo markets.

  The report uses indicators including China's pharmaceutical market of approximately RMB1.8 trillion, its medical device market of approximately RMB1.2 trillion, and an expected global CRO outsourcing rate of 62% by 2030 to assess industry potential.

• Innovative-Drug GlobalizationPatent Cliff and BD Transaction Structure Analysis

  Assess the overseas value of Chinese assets using the LOE gap at global pharmaceutical companies and structures such as out-licensing, NewCos, co-development, and co-commercialization.

  The report emphasizes that headline deal value alone may overstate the level of validation; true value depends on retained economic interests, milestone realization, rights structures, and global clinical translation capabilities.

• Policy TrackingNRDL, DRG/DIP, VBP, and Regulatory Event Calendar

  Assess the impact of policy on pharmaceuticals, services, and devices through medical insurance negotiations, drug formularies, hospital payment reform, and centralized procurement schedules.

  The report lists key events for the second half of 2026, including the NRDL, commercial insurance formulary, biosimilar VBP, DRG/DIP expansion, and regional medical device VBP.

• Sub-Industry ComparisonCross-Analysis of Fundamentals, Policy, and Capital Expenditure

  Compare different sub-industries within a common framework covering demand, costs, policy, capital expenditure, overseas expansion, and industry consolidation.

  The report separately assesses the drivers and risks of innovative drugs, cro/cdmo, medical devices, pharmacies, traditional Chinese medicine, distribution, and active pharmaceutical ingredients.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Chinese Innovative-Drug and Biotechnology Companies

  Directly benefit from global pharmaceutical patent cliffs and demand for Chinese assets overseas

  Strengths

  Talent, clinical costs, R&D efficiency, regulatory coordination, and diversified BD structures support globalization.

  Weaknesses

  Headline deal value does not equal true value; retained economic interests and global clinical acceptability must be assessed.

  Comparison

  Offer greater global growth elasticity than traditional generic drugs, but realization depends on clinical outcomes and transaction terms.

  Risks

  Intellectual property, corporate structure, overseas clinical design, regulatory acceptance, and milestone realization risks.

• Chinese cro/cdmo

  Benefit from rising global R&D outsourcing rates and China's increasing importance as a global R&D base

  Strengths

  Cost, efficiency, technical capabilities, regulatory environment, and growth in clinical trial initiations.

  Weaknesses

  Order recovery and capacity utilization still require validation, while capital expenditure cycles at some CDMOs may affect returns.

  Comparison

  Risks are more diversified than those of single-drug assets, but the sector is more exposed to global R&D budgets and outsourcing cycles.

  Risks

  Geopolitical policy, customer concentration, price competition, deterioration in book-to-bill, and slowing backlog growth.

• Chinese Medical Devices

  Linked to hospital capital expenditure, equipment upgrades, VBP, and overseas revenue

  Strengths

  Large domestic market, expected improvement in hospital capital expenditure in 2026, and stronger overseas commercial momentum for some companies.

  Weaknesses

  Regional VBP and medical insurance payment pressure may compress prices and margins.

  Comparison

  Compared with pharmaceuticals, the sector faces different policy variables and depends more on hospital budgets and product iteration.

  Risks

  Expansion of VBP, hospital fiscal pressure, import substitution competition, and overseas market access risks.

• Retail Pharmacies

  Affected by reforms to medical insurance individual accounts, tighter regulation, industry consolidation, and cost optimization

  Strengths

  Leading players can improve operating efficiency through acquisitions, franchising, and closure of inefficient stores.

  Weaknesses

  Weak same-store sales, consumer demand, price declines, and regulatory inspections continue to weigh on revenue.

  Comparison

  Lower growth than innovative drugs, but may offer earnings recovery driven by consolidation and expense optimization.

  Risks

  Continued store contraction, changes in medical insurance payment policies, price competition, and weak demand in lower-tier cities.

• Traditional Chinese Medicine

  Affected by consumer demand, raw material prices, medical insurance cost controls, and dividend characteristics

  Strengths

  Stable cash flow and relatively high payout ratios, with costs of some raw materials declining.

  Weaknesses

  Weak demand, costs, and falling tender prices continue to weigh on earnings.

  Comparison

  Lacks the high-growth narrative of innovative drugs but offers more pronounced defensiveness and shareholder returns.

  Risks

  Medical insurance cost controls, centralized procurement, raw material price volatility, and weak consumption.

• Active Pharmaceutical Ingredients

  Linked to export demand, price cycles, and the global supply-chain position

  Strengths

  High export revenue share, with certain categories holding important positions in global supply.

  Weaknesses

  Significant volatility in price cycles and the trade environment.

  Comparison

  More manufacturing- and cyclical-oriented than finished formulations and innovative drugs.

  Risks

  Price declines, trade friction, overseas regulation, and input-cost volatility.

Key data

• China Pharmaceutical Market SizeApproximately RMB1.8 trillionThe report states that China's pharmaceutical market accounts for approximately 15% of the global pharmaceutical market.
• China Medical Device Market SizeApproximately RMB1.2 trillionUsed to assess the domestic medtech market and capital expenditure potential.
• Hospital Capital Expenditure OutlookWeighted average growth rate of 4.7% in 2026Based on the China Hospital AlphaWise survey, in which more hospital executives expect capital expenditure to increase.
• Global CRO Outsourcing RateExpected to reach 62% by 2030The report believes the R&D outsourcing rate of global pharmaceutical companies will continue to rise.
• China Clinical CRO MarketExpected to recover significantly from 2025 to 2030Supported by cost, efficiency, technical capabilities, and the regulatory environment.
• Number of Pharmacy StoresApproximately 680,000 at the end of 2025Approximately 22,000 stores were closed net in 2025, and the industry may still contract by about 30% from its peak of approximately 700,000 stores over the next three to five years.
• Pharmacy Same-Store Sales GrowthDown 1.0% year over year in April 2026, up 0.3% year to dateAffected by regulatory inspections, weak consumption, and price declines.
• Natural Bovine Gallstone PriceDeclined from RMB1.65 million/kg at the beginning of 2025 to RMB520,000/kg in June 2026A pilot program for imported bovine gallstones has helped ease cost pressure in traditional Chinese medicine.
• Export Revenue Share of Chinese API Companies43% in 2024Shows the sensitivity of the API sector to overseas demand and the trade environment.
• U.S. Semaglutide DMF HoldersMore than 80% from ChinaReflects the important global supply position of Chinese API companies in certain popular categories.

Impact & implications

For investors, the opportunities identified by the report are not simple sector-wide beta exposures but involve structural differentiation: innovative-drug companies need to demonstrate global clinical translation, transaction structures, and retained rights; cro/cdmo companies require monitoring of orders, book-to-bill, backlog, and the recovery of global customers; medical devices depend on hospital capital expenditure, VBP effects, and overseas commercialization; while pharmacies and traditional Chinese medicine rely more on cost control, regulatory compliance, channel consolidation, and cash-flow quality.

Risks

• Insufficient global clinical trial design, patient composition, or regulatory acceptance causes overseas translation of Chinese innovative drugs to fall short of expectations.
• BD headline deal amounts are high but retained economic interests are insufficient, resulting in lower-than-expected true NPV and shareholder value.
• NRDL, DRG/DIP, VBP, and medical insurance payment reforms increase pressure on prices and margins.
• cro/cdmo order recovery is slower than expected, with deterioration in book-to-bill, backlog, or capacity utilization.
• Expansion of regional VBP for medical devices or hospital capital expenditure below expectations.
• Weak retail pharmacy consumption, regulatory inspections, and price declines continue to suppress same-store sales.
• API price cycles, export demand, and trade policy volatility affect earnings.

What to watch

• NRDL negotiations, the commercial insurance formulary, and the release of the final drug list in the second half of 2026.
• Potential biosimilar VBP developments in the second half of 2026 or the first half of 2027.
• Chinese innovative-drug clinical data presented at conferences including ASCO, EHA, ESMO, ASH, and SABCS.
• The quality of terms in Chinese pharmaceutical companies' out-licensing, NewCo, co-development, and co-commercialization transactions.
• cro/cdmo book-to-bill, backlog growth, customer mix, and capacity utilization.
• Hospital capital expenditure surveys, equipment upgrade policies, and progress of regional medical device VBP.
• Pharmacy same-store sales, net store closures, franchise expansion, and changes in medical insurance individual-account payments.
• Prices of traditional Chinese medicine raw materials, payout ratios, and changes in cost pressure.
• API exports, price trends, and the global supply landscape for key categories.